Pegfilgrastim

From Wikipedia, the free encyclopedia
(Redirected from Neulasta)

Template:Short description Template:DMCA Template:Short description Page Template:Infobox drug/styles.css has no content.

Page Module:Infobox/styles.css has no content.

Pegfilgrastim
Clinical data
Trade namesNeulasta
Biosimilarspegfilgrastim-apgf, pegfilgrastim-bmez, pegfilgrastim-cbqv, pegfilgrastim-fpgk, pegfilgrastim-jmdb, pegfilgrastim-pbbk, pegfilgrastim-pccg, pegfilgrastim-unne,[1] Armlupeg,[1][2][3] Cegfila,[4] Filpegla,[5] Dyrupeg,[6] Ennumo, Fulphila,[7] Fylnetra,[8] Grasustek,[9] Lapelga, Neutropeg, Niopeg,[10] Nyvepria, Pelgraz, Pelmeg,[11] Ristempa, Stimufend,[12][13] Tezmota,[14] Udenyca, Vivlipeg,[15] Ziextenzo[16][17]
AHFS/Drugs.comMonograph
MedlinePlusa607058
License dataPage Template:Plainlist/styles.css has no content.
Pregnancy
category		Page Template:Plainlist/styles.css has no content.
Routes of
administration		Subcutaneous
Drug classHematopoietic agents, colony-stimulating factors, immunostimulants
ATC codePage Template:Plainlist/styles.css has no content.
Legal status
Legal statusPage Template:Plainlist/styles.css has no content.
Pharmacokinetic data
Elimination half-life15–80 hrs
Identifiers
  • N-(3-Hydroxypropyl)Methionylcolony-stimulating Factor (human), 1-Ether with .Alpha.-Methyl-.Omega.-Hydroxypoly(Oxyethylene)
CAS NumberPage Template:Plainlist/styles.css has no content.
PubChem CIDPage Template:Plainlist/styles.css has no content.
PubChem SIDPage Template:Plainlist/styles.css has no content.
IUPHAR/BPSPage Template:Plainlist/styles.css has no content.
DrugBankPage Template:Plainlist/styles.css has no content.
ChemSpiderPage Template:Plainlist/styles.css has no content.
UNIIPage Template:Plainlist/styles.css has no content.
KEGGPage Template:Plainlist/styles.css has no content.
ChEBIPage Template:Plainlist/styles.css has no content.
ChEMBLPage Template:Plainlist/styles.css has no content.
NIAID ChemDBPage Template:Plainlist/styles.css has no content.
PDB ligandPage Template:Plainlist/styles.css has no content.
CompTox Dashboard (EPA)Page Template:Plainlist/styles.css has no content.
Chemical and physical data
FormulaC845H1343N223O243S9
Molar mass18802.90 g·mol−1
3D model (JSmol)Page Template:Plainlist/styles.css has no content.
Data page
Template:Infobox drug/data page link
Page Template:Nobold/styles.css has no content. ☒NcheckY (what is this?)Page Template:Nobold/styles.css has no content.  (verify)

Pegfilgrastim, sold under the brand name Neulasta among others, is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim.[22] It serves to stimulate the production of white blood cells (neutrophils).[22][24] Pegfilgrastim was developed by Amgen.[25]

Pegfilgrastim treatment can be used to stimulate bone marrow to produce more neutrophils to fight infection in patients undergoing chemotherapy.[26]

Pegfilgrastim has a human half-life of 15 to 80 hours, much longer than the parent filgrastim (3–4 hours).[27][26]

Pegfilgrastim was approved for medical use in the United States in January 2002, in the European Union in August 2002, and in Australia in September 2002.[25][23][28][29][30] It is on the World Health Organization's List of Essential Medicines.[31]

Medical uses

Pegfilgrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in people with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia; and to increase survival in people acutely exposed to myelosuppressive doses of radiation (hematopoietic subsyndrome of acute radiation syndrome).[22][32][33]

Society and culture

In January 2025, the Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Dyrupeg, intended to shorten the duration of neutropenia and help prevent febrile neutropenia after cytotoxic chemotherapy.[6] The applicant for this medicinal product is CuraTeQ Biologics s.r.o.[6] Dyrupeg is a biosimilar medicinal product that is highly similar to the reference product Neulasta, which was authorized in the EU in August 2002.[6] Dyrupeg was authorized for medical use in the European Union in March 2025.[6][34]

In June 2025, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Vivlipeg, intended to reduce the duration of neutropenia and the incidence of febrile neutropenia after cytotoxic chemotherapy.[15] The applicant for this medicinal product is Biosimilar Collaborations Ireland Limited.[15] Vivlipeg is a biosimilar medicinal product that is highly similar to Neulasta.[15] Vivlipeg was authorized for medical use in the European Union in August 2025.[15][35]

References

Page Template:Reflist/styles.css has no content.

  1. ^ a b Page Module:Citation/CS1/styles.css has no content."Lupin Receives Approval from U.S. FDA for Biosimilar Armlupeg (Pegfilgrastim-unne)" (Press release). Lupin. 1 December 2025. Retrieved 4 December 2025.
  2. ^ Page Module:Citation/CS1/styles.css has no content."Regulatory Decision Summary for Armlupeg". Drug and Health Products Portal. 16 August 2024. Retrieved 27 December 2024.
  3. ^ Page Module:Citation/CS1/styles.css has no content."Summary Basis of Decision for Armlupeg". Drug and Health Products Portal. 22 December 2024. Retrieved 25 January 2025.
  4. ^ a b Page Module:Citation/CS1/styles.css has no content."Cegfila EPAR". European Medicines Agency (EMA). 20 December 2019. Archived from the original on 11 June 2020. Retrieved 2 April 2020.
  5. ^ a b c Page Module:Citation/CS1/styles.css has no content."Filpegla | Therapeutic Goods Administration (TGA)". Archived from the original on 18 December 2022. Retrieved 18 December 2022.
  6. ^ a b c d e Page Module:Citation/CS1/styles.css has no content."Dyrupeg EPAR". European Medicines Agency (EMA). 30 January 2025. Retrieved 16 February 2025. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  7. ^ a b Page Module:Citation/CS1/styles.css has no content."Fulphila EPAR". European Medicines Agency (EMA). 24 September 2018. Archived from the original on 11 June 2020. Retrieved 2 April 2020.
  8. ^ a b Page Module:Citation/CS1/styles.css has no content."Fylnetra- pegfilgrastim injection". DailyMed. 26 May 2022. Archived from the original on 3 July 2022. Retrieved 19 June 2022.
  9. ^ a b Page Module:Citation/CS1/styles.css has no content."Grasustek EPAR". European Medicines Agency (EMA). 24 April 2019. Archived from the original on 11 June 2020. Retrieved 2 April 2020.
  10. ^ a b Page Module:Citation/CS1/styles.css has no content."Summary Basis of Decision for Niopeg". Drug and Health Products Portal. 1 September 2012. Retrieved 17 December 2024.
  11. ^ a b Page Module:Citation/CS1/styles.css has no content."Pelmeg EPAR". European Medicines Agency (EMA). 24 September 2018. Archived from the original on 11 June 2020. Retrieved 2 April 2020.
  12. ^ a b Page Module:Citation/CS1/styles.css has no content."Stimufend- pegflilgrastim-fpgk injection, solution". DailyMed. 15 September 2022. Archived from the original on 21 January 2023. Retrieved 21 January 2023.
  13. ^ a b Page Module:Citation/CS1/styles.css has no content."Stimufend EPAR". European Medicines Agency (EMA). 4 April 2022. Archived from the original on 21 April 2022. Retrieved 4 April 2022.
  14. ^ Page Module:Citation/CS1/styles.css has no content."Tezmota". NPS MedicineWise. 15 July 2021. Archived from the original on 29 September 2022. Retrieved 19 February 2022.
  15. ^ a b c d e Page Module:Citation/CS1/styles.css has no content."Vivlipeg EPAR". European Medicines Agency (EMA). 20 June 2025. Retrieved 26 June 2025. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  16. ^ a b Page Module:Citation/CS1/styles.css has no content."Ziextenzo EPAR". European Medicines Agency (EMA). 24 September 2018. Archived from the original on 11 June 2020. Retrieved 2 April 2020.
  17. ^ Page Module:Citation/CS1/styles.css has no content."Summary Basis of Decision (SBD) for Ziextenzo". Health Canada. 23 October 2014. Archived from the original on 30 May 2022. Retrieved 29 May 2022.
  18. ^ a b Page Module:Citation/CS1/styles.css has no content."Ziextenzo". Therapeutic Goods Administration (TGA). 13 December 2019. Archived from the original on 20 October 2021. Retrieved 25 August 2020.
  19. ^ Page Module:Citation/CS1/styles.css has no content."Pegfilgrastim Use During Pregnancy". Drugs.com. 9 December 2019. Archived from the original on 5 December 2020. Retrieved 13 July 2020.
  20. ^ Page Module:Citation/CS1/styles.css has no content."Neulasta Pre-Filled Syringe - Summary of Product Characteristics (SmPC)". (emc). 1 June 2021. Archived from the original on 15 January 2021. Retrieved 11 October 2021.
  21. ^ Page Module:Citation/CS1/styles.css has no content."Neulasta On Body Injector - Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 17 January 2021. Retrieved 11 October 2021.
  22. ^ a b c d Page Module:Citation/CS1/styles.css has no content."Neulasta- pegfilgrastim kit Neulasta- pegfilgrastim injection". DailyMed. Archived from the original on 15 July 2021. Retrieved 14 July 2021.
  23. ^ a b Page Module:Citation/CS1/styles.css has no content."Neulasta EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 11 June 2020. Retrieved 2 April 2020.
  24. ^ Walsh, G, Spada, S. "Epogen/Procrit" in: Directory of approved biopharmaceutical products. CRC Press, 2005, pp. 136–37.
  25. ^ a b Page Module:Citation/CS1/styles.css has no content."Drug Approval Package: Neulasta (Pegfilgrastim) NDA #125031". U.S. Food and Drug Administration (FDA). 25 October 2004. Archived from the original on 30 March 2021. Retrieved 11 June 2020.
  26. ^ a b Page Module:Citation/CS1/styles.css has no content."Pegfilgrastim Monograph for Professionals". Drugs.com. 22 August 2019. Archived from the original on 7 March 2016. Retrieved 11 June 2020.
  27. ^ Page Module:Citation/CS1/styles.css has no content.Ho, Rodney J. Y.; Gibaldi, Milo, eds. (2004). "Pegfilgrastim". Biotechnology and Biopharmaceuticals: Transforming Proteins and Genes into Drugs. John Wiley & Sons. pp. 157–159. ISBN 978-0-471-45027-6. Archived from the original on 20 October 2021. Retrieved 10 November 2020.
  28. ^ Page Module:Citation/CS1/styles.css has no content."Summary for ARTG Entry: 82873 Neulasta pegfilgrastim rbe 6mg/0.6mL injection syringe with stelmi needle shield" (PDF). Therapeutic Goods Administration (TGA).[dead link]
  29. ^ Page Module:Citation/CS1/styles.css has no content."NEULASTA pegfilgrastim (Rbe) 6mg/0.6mL injection syringe with automatic needle guard (166387) | Therapeutic Goods Administration (TGA)". Archived from the original on 18 December 2022. Retrieved 18 December 2022.
  30. ^ Page Module:Citation/CS1/styles.css has no content."NEULASTA pegfilgrastim rbe 6mg/0.6mL injection syringe with stelmi needle shield (82873) | Therapeutic Goods Administration (TGA)". Archived from the original on 18 December 2022. Retrieved 18 December 2022.
  31. ^ Page Module:Citation/CS1/styles.css has no content.World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
  32. ^ Page Module:Citation/CS1/styles.css has no content.Cerchione C, Catalano L, Peluso I, Nappi D, Di Perna M, Salvatore D, et al. (December 2016). "Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone". Supportive Care in Cancer. 24 (12): 4835–4837. doi:10.1007/s00520-016-3430-9. PMC 5082581. PMID 27726031.
  33. ^ Page Module:Citation/CS1/styles.css has no content.Parker SD, King N, Jacobs TF (November 2020). "Pegfilgrastim". StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. PMID 30422488. Archived from the original on 20 October 2021. Retrieved 5 November 2020.
  34. ^ Page Module:Citation/CS1/styles.css has no content."Dyrupeg PI". Union Register of medicinal products. 31 March 2025. Retrieved 26 June 2025.
  35. ^ Page Module:Citation/CS1/styles.css has no content."Vivlipeg PI". Union Register of medicinal products. 1 September 2025. Retrieved 30 September 2025.

Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Template:Cytokine receptor modulators Template:Growth factor receptor modulators Lua error in mw.title.lua at line 404: bad argument #2 to 'title.new' (unrecognized namespace name 'Portal'). Lua error in package.lua at line 80: module 'Module:Authority control/config' not found.

Retrieved from "https://cosmopedia.co/index.php?title=Pegfilgrastim&oldid=1251763"